With the development of pharmaceutical technology, there are more and more drugs for the clinical treatment of rheumatic diseases, especially the emergence of biologics for the treatment of ankylosing spondylitis and rheumatoid arthritis, which bring a boon to patients with rheumatic diseases. Today, we briefly introduce some commonly used anti-rheumatic biologics in clinical practice. At present, the main anti-rheumatic biologics frequently used in clinical practice are Enzyme (etanercept), Ixepro, Qiangk, Ambienol, Xumel (adalimumab), Classic (infliximab), Yamiro (tolclozumab), and so on. Next I will briefly introduce these biological agents. 1, fusion protein class family (technical terms do not care what exactly means): the main members of the family are Enzyme (Enacip), Ixep, prednisol, Ambienol. Enzyme (Enacip) is the world’s first fully humanized soluble tumor necrosis factor (mentioned tumor necrosis factor, not to say that you have a tumor disease. Whenever I talk to patients about this term, they are particularly sensitive to the word “tumor”. Tumor necrosis factor is a cytokine that was first discovered to kill tumor cells. (Tumor necrosis factor is an inflammatory mediator, in other words, it may cause inflammation.) The receptor fusion protein-based biologic was marketed abroad in 1998 and has 17 years of clinical use and over four million patient-years of evidence-based medicine, and is produced by Pfizer, a cosmic pharmaceutical company known to all of you. Enzyme is primarily used for the treatment of rheumatoid arthritis in adult patients with moderately to severely active rheumatoid arthritis who are not responding to slow-acting antirheumatic drugs, including methotrexate (if not contraindicated). Etanercept alone or in combination with methotrexate has been shown to reduce the rate of progression of joint damage and improve joint function. Adult patients with severe active ankylosing spondylitis who have failed to respond to conventional therapy may be treated with etanercept. Enzyme, Qantac and Amphenol are bio-analogues of Enzyme (etanercept), which are drugs for the treatment of rheumatoid and ankylosing spondylitis, with the same indications as Enzyme, and are manufactured and sold by domestic pharmaceutical companies CITIC Guojian, Saijin Pharmaceutical and Haisheng Pharmaceutical, respectively, at a lower price than imported biologics. Enzyme, Yicep, Qiangke and Amphenol their usage is generally twice a week subcutaneous injection or once a week subcutaneous injection. 2, monoclonal antibody family: family members of biological agents are mainly Xumel (adalimumab), class gram (infliximab), Yamiro (tolclozumab). (1) Xumilor (adalimumab): humanized monoclonal antibody against human tumor necrosis factor, mainly used for the treatment of rheumatoid arthritis and ankylosing spondylitis, is produced by the United States of America’s AbbVie Pharmaceuticals, subcutaneous injection every two weeks (14 days) a single dose of 40mg, the drug package is 40mg a. (2) class gram (infliximab): human-mouse chimeric monoclonal antibody, mainly for the treatment of rheumatoid arthritis and ankylosing spondylitis, as well as Crohn’s disease (a chronic enteritis), but also for patients with severe psoriasis or psoriatic arthritis, it is manufactured and sold by Xi’an Janssen. The dose is usually calculated based on the patient’s body weight. Unlike Xumel, which is administered subcutaneously, Sycamore is administered intravenously and therefore needs to be administered in a hospital. For patients with rheumatoid arthritis, the first dose of 3 mg/kg (3mg/kg) is calculated to be 180 mg for a 60 kg body weight, and two doses of 200 mg are often given to avoid wastage. /For patients with ankylosing spondylitis, an initial dose of 5 mg/kg followed by the same dose at 2 weeks and 6 weeks after the initial dose and at 6-week intervals thereafter may be considered. However, it is worth noting that allergic reactions occasionally occur, so the titration is usually preceded by an injection of dexamethasone to prevent allergic reactions. To summarize the use of Classic, except for the first and second doses, which are given two weeks apart, you need to wait another month after the second dose before giving the third dose. After the fourth time, rheumatoid arthritis is given every two months, and ankylosing spondylitis is given every one and a half months. (3) Yamiro (tolimumab injection): recombinant humanized anti-human interleukin-6 receptor monoclonal antibody, indication for the treatment of rheumatoid arthritis, is produced and sold by Roche Pharmaceuticals, the dosage is 8mg/kg (the specific dosage is calculated according to body weight, for example, weight 50kg, the need for Yamiro is 50Kg * 8mg/Kg = 400mg), need to be in the hospital It is administered intravenously in a hospital. The drug is administered once a month. Each of these biological agents has its own advantages. They are often more effective than oral medication. However, it is important to be screened for tuberculosis and viral hepatitis before using biologics. Only eligible patients should be treated with biologics.